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ttp://dx.doi.org/10.1016/j.ajpath.2013.04.025We have recently shown acetylation of tau at lysine residue 280 (AC-K280) to be a disease-speciﬁc
modiﬁcation in Alzheimer disease (AD), corticobasal degeneration, and progressive supranuclear palsy,
likely representing a major regulatory tau modiﬁcation. Herein, we extend our observations using IHC
with a polyclonal antibody speciﬁc for AC-K280. Thirty brain regions were examined in argyrophilic grain
disease (AGD; nZ 5), tangle-predominant senile dementia (TPSD; nZ 5), Pick disease (nZ 4), familial
AD (FAD; nZ 2; PSEN1 p.G206A and p.S170P), and frontotemporal dementia with parkinsonism linked to
chromosome-17 (FTDP-17; nZ 2; MAPT p.P301L and IVS10þ 16). All AGD, TPSD, FAD, and FTDP-17 cases
had signiﬁcant AC-K280 reactivity that was similar in severity and distribution to phosphorylated tau. AC-
K280 robustly labeled grain pathological characteristics in AGD and was predominantly associated with
thioﬂavin-Sepositive neuroﬁbrillary tangles and less reactive in neuropil threads and extracellular
tangles in TPSD and FAD. Thioﬂavin-Senegative neuronal and glial inclusions of patients with FTDP-17
were robustly AC-K280 reactive. A low degree of AC-K280 was found in a subset of 4-repeat tau-
containing lesions in Pick disease. AC-K280 is a prominent feature of both neuronal and glial tau
aggregations in tauopathies of various etiologies. The close association of AC-K280 with amyloid and pre-
amyloid conformations of tau suggests a potential role in tangle maturation and, thus, could serve as
a useful biomarker or therapeutic target in a variety of tauopathies. (Am J Pathol 2013, 183: 344e351;
http://dx.doi.org/10.1016/j.ajpath.2013.04.025)Supported by NIH grants P30 AG10124, AG17586, and T32-AG000255
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payments through University of Pennsylvania licenses.Tauopathies are a heterogeneous group of neurodegenerative
diseases characterized by abnormal conformations of tau
proteins incorporated into inclusions and resulting in neu-
ronal loss and gliosis. Pathogenic mutations in theMAPT tau
gene causing frontotemporal dementia with parkinsonism
linked to chromosome-17 (FTDP-17),1 with characteristic
tau lesions at autopsy, provide compelling evidence of
a central role of tau aggregation in disease pathogenesis.
Tau is subject to multiple post-translational modiﬁcations
that, in disease states, may become dysregulated and contribute
to pathological aggregation.2 Previously, our group3 and
others4 have found that tau is modiﬁed by acetylation on
lysine residues within the microtubule (MT)ebinding domain
(MTBD). Two main categories of tau isoforms exist, based on
alternative splicing of exon 10 for inclusion or exclusion of the
secondMTBDfor a total of 3 (3R) or 4 (4R)MTBDrepeats.Westigative Pathology.
.found acetylation of lysine 280 (AC-K280) in the second
MTBD in 4R tau to be disease speciﬁc, resulting in both
decreased microtubule binding and increased ﬁbrillization
in vitro.3 Furthermore, AC-K280 is a prominent marker of
pathological characteristics in Alzheimer disease (AD), corti-
cobasal degeneration (CBD), and progressive supranuclear
palsy (PSP).5 Herein, we further examine the AC-K280
Acetylated Tau in Tauopathiesmodiﬁcation in other sporadic and hereditary tauopathies
characterized by insoluble 4R tau-predominant ﬁlaments,
including argyrophilic grain disease (AGD), tangle-
predominant senile dementia (TPSD), FTDP-17, and familial
AD (FAD) cases caused by presenillin-1 (PSEN1) mutations.
We also examined cases of the predominantly 3R tauopathy,
Pick disease (PiD), because heterogeneity exists in the tau iso-




Patientswere seen at theUniversity of Pennsylvania Perelman
School of Medicine (Philadelphia) Alzheimer’s Disease
Center or Frontotemporal DegenerationCenter, and autopsies
were performed at the Center for Neurodegenerative Disease
Research. Autopsies were performed with informed consent,
and all procedures were done in accordance with the local
Institutional Review Board guidelines. Patient demographics
were obtained from our integrated neurodegenerative disease
database9 (Supplemental Table S1). Neuropathological as-
sessment and diagnosis were performed as reported previ-
ously10 using established criteria.11,12 Tau and amyloid b
pathological characteristics were staged according to Braak
and Braak13 and the Consortium to Establish a Registry for
Alzheimer’s Disease14 criteria, respectively. AGD cases were
staged according to Ferrer et al.15 Thirty areas were sampled
and analyzed for ﬁve cases each of AGD and TPSD, four
cases of PiD, and several hereditary FAD and FTDP-17 cases
[n Z 1: PSEN1 p.G206A,16 PSEN1 p.S170P, MAPT
p.P301L,1 and MAPT IVS10 þ 16 (c.915 þ 16C>T)1]. We
also examined available regions in two nonneurodegenerative
control cases (Braak stage 0) (Supplemental Table S1).
The PSEN1 p.S170P mutation has not been previously
reported, but it is likely pathogenic in view of the extremely
young age of disease onset (27 years) in this patient and the
family history of AD among the kindred of this patient
(Supplemental Figure S1), as well as a similar reported
pathogenic mutation at this residue (p.S170F).17
IHC Data
Fresh tissue was sampled at autopsy and ﬁxed in 70% ethanol/
150 mmol sodium chloride, embedded in parafﬁn, and cut into
sections (6 mm thick). Immunohistochemistry (IHC) was per-
formed, as previously described,5 using a rabbit-generated
polyclonal antibody speciﬁc for tau modiﬁed with an acetyl
group at the 280 lysine (K) residue3 (AC-K280; 1:250 to
1:1000 dilution) and an avidin-biotin complex detection
system (VECTASTAIN ABC kit; Vector Laboratories, Bur-
lingame, CA) with 3,30-diaminobenzidine as the chromogen.
AC-K280 speciﬁcity for themodiﬁed lysine residue has been
described in detail.3 Mouse monoclonal antibodies (mAbs)
speciﬁc for other tau epitopes were used herein, and theyThe American Journal of Pathology - ajp.amjpathol.orginclude phosphorylated tau [PHF-118; 1:500 to 1:1000;
courtesy of Dr. Peter Davies (Albert Einstein College of
Medicine, Department of Pathology, Bronx, NY)] and 3R
(RD319; 1:2500 to 1:5000; Millipore, Billerica, MA) and 4R
(RD419; 1:5000 to 1:10,000; Millipore) tau isoforms.
Antigen retrieval was performed by using 88% formic acid
for AC-K280 and RD3 or boiling with a citric acid
unmasking solution (Vector Laboratories) for RD4.
Double-label immunoﬂuorescence experiments were per-
formed as described5 using AC-K280 and tau-speciﬁc mAbs
or thioﬂavin-S (ThS) amyloid dye staining for ﬁbrillar
inclusions and Alexa Fluor 488 and 594 species-speciﬁc
conjugated secondary antibodies (Invitrogen, Grand Island,
NY). To conﬁrm the 4R tau predominance in AGD grains
and presence of 4R tau in PiD cases, serial sections and
double-label experiments with AC-K280 and RD3/RD4were
performed on hippocampal sections of AGD (n Z 4) and
three areas of high AC-K280 reactivity in one PiD case
(anterior cingulate gyrus, motor cortex, and temporal cortex).
ThS and AC-K280 double labeling was also examined in
these regions for AGD and PiD and, in addition, in TPSD
hippocampus (n Z 4), FAD hippocampus or frontal cortex
(nZ 2), and FTDP-17 hippocampus or temporal neocortex
(n Z 2). Digital images of immunoﬂuorescence were ob-
tained with an Olympus BX 51 microscope equipped with
a bright-ﬁeld and ﬂuorescence light source with a DP-71
digital camera (Olympus, Center Valley, PA) and DP
manager software version 3.1.1.208 (Olympus) and overlaid
into a merge channel using Adobe Photoshop version 9.0.2
(Adobe Systems, San Jose, CA).Genetic Analysis
For the hereditary cases in this study, DNA was extracted
from peripheral blood samples or brain tissue using the
manufacturer’s protocol (Flexigene; Qiagen, Valencia,
CA) or the Quick-Gene DNA whole blood kit (Autogen,
Holliston, MA). DNA sequence analysis of the entire
coding region of PSEN1 and targeted regions of MAPT
known to harbor pathogenic mutations (exons 1 and 9 to
13) was performed as previously described.16,20 Data were
analyzed for identiﬁcation of mutations with Mutation
Surveyor software version 4.0.7 (Soft Genetics, State
College, PA).Microscopic and Statistical Analysis
Regional distribution and severity of AC-K280 were
compared with PHF-1 across 30 representative central
nervous system regions and graded on a semiquantitative
scale, as previously described5 (0, none or rare patholog-
ical feature; 1, weak; 2, moderate; and 3, strong). Median
semiquantitative scores for grouped data were calculated
for each region per disease group using SPSS, version 19.0
(SPSS Inc., Chicago, IL).345
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Regional Distribution
Detailed neuropathological assessment in 30 representative
cortical and subcortical regions of the CNS revealed AC-
K280 in a similar distribution and severity to the well-
described PHF-1 phosphorylated-epitope of tau (Ser396/
404)18 in AGD, TPSD, FAD, and FTDP-17 cases (Figure 1
and Supplemental Tables S2, S3, and S4). AC-K280
immunoreactivity was not found in areas negative for
PHF-1, and, similarly, in regions with weak or rare PHF-1
pathological features, there was often no detectable AC-
K280. This was also true in control cases, in which AC-
K280 was limited to rare (one to three tangles) in the
cornu ammonis in one case; these were also detected with
PHF-1 in an adjacent section (Figure 2 and Supplemental
Table S4). Only rarely in FTDP-17 did AC-K280 immu-
noreactivity appear slightly more prominent than PHF-1
(Supplemental Table S4). PiD cases were largely negative
for AC-K280; however, a subset of regions in each PiD case
contained a varying degree of AC-K280 immunoreactivity
(Table 1). In most instances when AC-K280 immunoreac-
tivity was present, it was found in rare (one to ﬁve per slide)
glial inclusions or Pick bodies, although one case had three
regions with an abundance of AC-K280 lesions. The fourth
case had only rare AC-K280 tau pathological characteristics
in the entorhinal cortex of the hippocampus.Figure 1 Regional distribution and severity of AC-K280epositive tau path
K280epositive tau pathological characteristics based on median semiquantitative
map of median severity score ranging from no pathological characteristics (0, w
regions evaluated include the following: 1, midfrontal cortex gray matter; 2, oribi
gray matter; 5, superior/midtemporal cortex gray matter; 6, angular cortex gray m
9, midbrain; 10, pons; 11, medulla; 12, cervical spinal cord; 13, cerebellar cortex
substantia nigra; 18, midfrontal cortex white matter; 19, superior/midtemporal c
anterior cingulate gyrus white matter; 24, motor cortex white matter; 25, sensor
entorhinal cortex gray matter; 29, hippocampal formation (cornu ammonis 1 to 4
346Morphological Assessment
Argyrophilic Grain Disease
AC-K280 was robust in tau-positive comma-shaped grains in
all ﬁve AGD cases studied herein (Figure 2), which were
largely restricted to limbic areas (one stage II and four stage
III). PHF-1epositive intracellular pretangles and neuroﬁbril-
lary tangles (NFTs), in addition to lightly tau-reactive swollen
achromatic ballooned neurons and coiled bodies in adjacent
white matter, were also labeled by AC-K280 (Figure 2). AC-
K280 was found in predominantly ThS-positive NFTs and
variably ThS-positive grains (Figure 3). Comparison with
isoform-speciﬁc tau mAbs conﬁrmed the predominance of 4R
tau in grains, because the 4R-speciﬁc tau mAb (RD4) dis-
played a similar predominance of intracellular NFTs and
grains toAC-K280,whereas a 3R-speciﬁcmAb (RD3)mainly
labeled AD-associated extracellular ghost tangles and diffuse
neuropil threads (NTs) that were not well labeled by the
AC-K280 antibody (Supplemental Figure S2). AC-K280
colocalized well with RD4 in grains that were largely RD3
negative, and colocalized with both isoform-speciﬁc mAbs in
intracellular NFTs (Supplemental Figure S2).
Tangle-Predominant Senile Dementia
TPSD cases had a predominance of PHF-1ereactive NFTs
similar to AD in the absence of signiﬁcant amyloid b deposits
(Supplemental Table S1). AC-K280 was a prominent feature
of intracellular NFTs and less conspicuous in extracellularological characteristics in patients with AGD or TPSD. Heat map of AC-
score for AGD (nZ 5) (A) and TPSD (n Z 5) (B). Bar graph depicts color
hite) to strong reactivity (3, red). Gray regions were not evaluated. Brain
tofrontal cortex gray matter; 3, motor cortex gray matter; 4, sensory cortex
atter; 7, visual cortex gray matter; 8, anterior cingulate cortex gray matter;
; 14, cerebellar white matter; 15, dentate nucleus; 16, hypothalamus; 17,
ortex white matter; 20, lentiform nucleus; 21, striatum; 22, amygdala; 23,
y cortex white matter; 26, angular cortex white matter; 27, thalamus; 28,
/subiculum); and 30, entorhinal cortex white matter.
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Acetylated Tau in Tauopathiesghost tangles and diffuse scattered NTs (Figure 2). Most AC-
280ereactive NFTs in CA-1 were ThS positive (Figure 3). A
subset of cases had more widespread tau pathological char-
acteristics outside of the medial temporal lobe structuresThe American Journal of Pathology - ajp.amjpathol.org(Braak V to VI, n Z 2). These cases had abundant tau-
positive tangles and threads in the medial and lateral
temporal lobe cortical regions, with occasional tau-positive
glial inclusions largely restricted to gray matter, with some
compact lesions reminiscent of tufted astrocytes in PSP and
other, more diffuse, lesions resembling astrocytic plaques of
CBD. However, the lack of signiﬁcant white matter tau
pathological characteristics and infrequent tau inclusions in
the brainstem precluded these diagnoses and, thus, these
ﬁndings were most consistent with a diagnosis of TPSD. AC-
K280 immunoreactivity appeared similar in these cases, with
prominent deposition in neuronal tangles and glial lesions,
with minimal positivity in NTs or extracellular ghost tangles.
Familial AD
Both the PSEN1 p.G206A and p.S170P FAD cases displayed
typical AD tau pathological features, with widespread NTs,
NFTs, and neuritic plaques throughout cortical and, to
a lesser degree, subcortical structures (Supplemental Table
S4). Similar to sporadic AD,5 AC-K280 stained all forms
of neuroﬁbrillary pathological features but was most prom-
inent in ThS-positive intracellular NFTs and large dystrophic
neurites associated with neuritic plaques and was less reac-
tive to other NTs and extracellular NFTs (Figures 2 and 3).
Frontotemporal Dementia with Parkinsonism Linked to
Chromosome-17
FTDP-17 cases had microscopic ﬁndings consistent with
previous reports of abundant and widespread tau pathological
characteristics, albeit in different distributions in cases that
resembled PSP or CBD versus other phenotypic manifes-
tations of MAPT gene mutations.21,22 The p.P301L case
showed widespread strong immunoreactivity in tau deposits
throughout cortical and subcortical gray matter and, to a lesser
extent, white matter (Supplemental Table S4). Pleomorphic
neuronal tangles were prominent in superﬁcial and deep
cortical layers and were robustly reactive with AC-K280,
whereas associated diffuse threads seen with PHF-1 were
less evident in AC-K280estained sections (Figure 2). Pick-
like bodies were rarely observed with either epitope. GlialFigure 2 Acetylated and hyperphosphorylated tau pathological char-
acteristics in sporadic and hereditary tauopathies. AeP: Representative
images of AC-K280 staining and B-R display PHF-1 staining. Sections from
the amygdala in AGD show prominent AC-K280ereactive grains (arrow-
heads; A and C) and neuroﬁbrillary tangles (NFTs; asterisk; A) and ballooned
neurons (asterisk; C) similar to PHF-1 (B and D). AC-K280 reactivity in the
cornu ammonis (CA-1) region of the hippocampus in TPSD is seen mostly in
intracellular tangles (arrow; E), with less prominent staining of threads and
extracellular ghost tangles labeled by PHF-1 (F). CA-1 region of the hippo-
campus of a PSEN1 case (p.S170P) displays typical AD pathological charac-
teristics, with AC-K280 mainly in tangles (asterisk) and neuritic plaques
(arrow; G) and less prominent in diffuse threads than PHF-1 (H). Superior
temporal cortex (STC) of FTDP-17 cases (p.P301L and IVS10 þ 16) have
ACK280-reactive neuronal inclusions (I and M) and less prominent threads
than PHF-1 (J and N) in gray matter (GM) and a similar burden of glial tau
pathological features in white matter (WM; arrow; K and L). Non-
neurodegnerative disease control superior temporal cortex showing an
absence of AC-K280 (Q) and PHF-1 reactivity (R). Scale barZ 100 mm (R).
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Table 1 Summary of AC-K280 Reactivity in PiD Cases
Region
Case no.
1 2 3 4
Motor DDD Rare 0 NA
Striatum 0 0 þþ 0
Lentiform 0 0 Rare 0
Thalamus 0 0 Rare NA
Hypothalamus Rare D NA NA
Midbrain 0 0 0 0
Substantia nigra 0 0 Rare 0
Pons 0 0 0 0
Locus coeruleus 0 0 Rare 0
Cerebellar cortex 0 0 0 0
Dentate nucleus or cerebellum 0 0 0 0
Medulla 0 0 0 0
Cervical spinal cord 0 0 0 0
Midfrontal cortex Rare Rare þ 0
Orbital frontal cortex 0 Rare 0 0
Anterior cingulate cortex DDD 0 þ 0
Sensory cortex Rare 0 NA 0
Temporal cortex DDD 0 0 0
Angular cortex Rare 0 0 0
Visual cortex 0 0 NA 0
Entorhinal cortex or hippocampus Rare Rare 0 Rare
Cornu ammonis or hippocampus 0 0 0 0
Dentate gyrus or hippocampus 0 0 0 0
Amygdala Rare D 0 0
þ, weak; þþ, moderate ; þþþ, strong.
NA, tissue not available.
Figure 3 Colocalization of acetylated tau with ﬁbrillar (ThS þ) and
nonﬁbrillar (ThS ) tau inclusions. A: AGD entorhinal cortex (ERC) shows
AC-K280ereactive grains that are largely ThS negative (asterisks) and a ThS-
positive AD-associated tangle (arrow). B: Cornu ammonis region (CA-1) of
TPSDshowingmostlyAC-K280 in ThS-positive intracellular tangles (arrows) and
a subset of ThS-negative pretangles (asterisks). C: CA-1 region of FAD (S170P)
showing AC-K280ereactive tangle (arrows) and large dystrophic neurites
(asterisks) associated with a neuritic plaque. Tau lesions robustly positive for
AC-K280 in the temporal cortex of p.P301L (D) and IVS10 þ 16 FTDP-17 (E)
cases were minimally reactive to ThS (asterisks). Scale barZ 100 mm (E).
Irwin et alpathological features were moderate and mainly found in
coiled bodies and astrocytic lesions in white matter, both of
which were reactive to AC-K280 (Figure 2). In contrast, the
IVS10 þ 16 case had less prominent neuronal tau inclusions
and threads in graymatter and, instead, strong immunostaining
in white matter glial pathological features throughout the
neocortex and limbic cortices (Figure 2). Glial pathological
features were robustly positive for AC-K280 and, in rare
instances, slightly more prominent than PHF-1 (Supplemental
Table S4). AC-K280ereactive pathological characteristics in
FTDP-17 cases were largely negative for ThS (Figure 3). In
summary, AC-K280 was a prominent feature of the varied
glial and neuronal inclusions and less common in diffuse
threads seen in these FTDP-17 cases.
Pick Disease
Although PHF-1 and RD3 staining revealed numerous tau-
positive inclusions and diffusely distributed NTs, only
a minimal subset of tau lesions in the PiD cases was AC-K280
immunoreactive, and these included Pick bodies and compact
astrocytic inclusions (Supplemental Figure S3). Areas with
strong AC-K280 immunostaining in neuronal Pick body and
glial inclusions were conﬁrmed to contain 4R tau through
comparison of serial sections and double labeling with RD4.
The morphological characteristics of the AC-K280epositive
inclusions were similar to the RD4-stained inclusions and
both colocalized in neuronal and glial lesions, whereas double348labeling with RD3 demonstrated that some RD3-labeled
inclusions colocalized in the AC-K280epositive tau patho-
logical characteristics, but most often RD3 positivity did not
colocalize in AC-K280 (Supplemental Figure S3). PiD
inclusions, including those reactive to AC-K280, wereweakly
reactive for ThS (Supplemental Figure S3).
Discussion
We extend our previous studies of acetylated tau patho-
logical characteristics by documenting the presence of AC-
K280 immunoreactivity in the hallmark tau lesions of AGD,
TPSD, FAD, and FTDP-17 in a similar pattern and severity
to a well-annotated phosphorylated-epitope (Ser396/404).
Furthermore, we have also demonstrated the disease-speciﬁc
nature of the AC-K280 modiﬁcation because little or no AC-
K280 reactivity was found in the control cases examined
herein (Supplemental Table S4) or in previous studies.3,5
AC-K280 also detected tau pathological characteristics in
PiD, although to a much lesser extent and more variable
degree, reﬂecting the low burden of 4R tau inclusions in most
PiD cases. PiD is considered to be a 3R tauopathy, although
some cases have been found to have a variable, butajp.amjpathol.org - The American Journal of Pathology
Acetylated Tau in Tauopathiessigniﬁcant, burden of 4R tau-positive lesions or insoluble 4R
species of pathological tau.6e8 Indeed, we found minimal
AC-K280 immunoreactvity in PiD, which corresponded to
4R-containing lesions within individual cases. Interestingly,
AC-K280 was found in both 3R-positive and 3R-negative tau
inclusions, which probably reﬂects the presence of low levels
of 4R tau in some of these inclusions. These results highlight
the heterogeneity of pathological features within and
between individuals with PiD and further implicate the AC-
K280 modiﬁcation in pathological tau aggregations of
multiple etiologies.
AGD is a sporadic tauopathy associated with advanced
aging23,24 and cognitive impairment,25,26 bywhich tau-positive
grains have been localized to apical and basal dendrites27 and
contain a predominance of 4R tau.28e30 Indeed, we found
robust reactivity for AC-K280 in grain pathological features of
all ﬁve AGD brains examined herein, which exclusively
colocalized with another 4R-speciﬁc epitope detected by the
RD4 mAb. We found AC-K280 reactivity in AD-associated
intracellular tangles as well, and the common association of
AD pathological characteristics and AGD suggests that
formation of neuroﬁbrillary and grain pathological character-
istics may be mechanistically linked.26 Indeed, grains contain
manyof the samephosphorylation epitopes asADNFTs,31 and
herein we ﬁnd that AGD grain pathological features and AD-
like NFTs share the AC-K280 modiﬁcation as well. The
explanation for the discrepancy between robust AC-K280 in
grains and weak NT staining is not clear, but this may reﬂect
differences in deacetylase activity within the cytosolic
compartments of neurons, or differing mechanisms of inclu-
sion formation in grains versus NTs.
These ﬁndings are in contrast to a recent report by
Grinberg et al,32 who found a conspicuous absence of AC-
tau in grain pathological features in AGD, despite reactivity
in AD-type NFTs in these cases, using a novel monoclonal
antibody speciﬁc for acetylation of tau at the nearby lysine
residue 274 (AC-K274).32 One possibility for this discrep-
ancy is the effect of ﬁxatives used for tissue preparation,
because other tau antibodies for epitopes in the MTBD label
varying morphological characteristics of tau inclusions,
depending on tissue ﬁxation.33 Indeed, we have found AC-
K280 to be sensitive to formalin ﬁxation, requiring the use
of tissue ﬁxed in 70% ethanol with 150 mmol/L NaCl for
visualization of pathological characteristics in our studies (DJ
Irwin, TJ Cohen, VMY Lee, JQ Trojanowski, unpublished
observations). Notably, the study of Grinberg et al32 did test
the temporal effects of formalin ﬁxation on AC-K274 and
found that the formalin ﬁxation longer than 72 hours resulted
in decreased signal, but they did not examine other ﬁxatives.
Thus, these two epitopes could be differentially exposed in
grain pathological characteristics when AGD tissues are ﬁxed
in formalin versus ethanol. Another possibility for these
discrepancies is that AC-K274 is located in the ﬁrst MTBD,
which is present in both 3R and 4R tau isoforms, whereas AC-
K280 is found exclusively in 4R tau because of its presence in
the second MTBD; thus, the difference in speciﬁc AC tauThe American Journal of Pathology - ajp.amjpathol.orgepitopes detected by these antibodies could be responsible for
these observations as well.
Notably, we recently demonstrated that tau possesses a
novel enzymatic activity as a acetyltransferase with an
amino acid sequence and functional similarities to members
of the MYST family of enzymes.34 In this study, we
proposed that tau acetylates itself (autoacetylation) as part of
an autoinhibitory signaling mechanism to prevent tau-MT
interactions, and we also demonstrated that tau phosphory-
lation within the repeat regions could enhance tau autoa-
cetylation at K280.34 Future studies examining the effect of
different phospho-tau epitopes on tau acetylation are needed
to elucidate the biochemical interplay between these modi-
ﬁcations and the complex combinatorial set of modiﬁcations
that affect normal tau functions and contribute to the path-
ogenesis of tau pathological characteristics. Finally, we
speculate that the detection of diverse disease-speciﬁc tau
modiﬁcations in cerebral spinal ﬂuid of patients could aid in
the antemortem diagnosis of tauopathies.
TPSD is associated with advanced aging and shows
a distribution of neuroﬁbrillary tau pathological character-
istics that are similar to AD, and these pathological char-
acteristics contain both 3R and 4R tau isoforms.35,36 Indeed,
AC-K280 was highly associated with, but not exclusive to,
ThS-positive intracellular NFTs in TPSD and FAD and, less
commonly, in NTs and extracellular ghost tangles similar to
AD. In contrast, AC-K280 was also prominent in ThS-
negative neuronal pretangles and glial inclusions of
FTDP-17 (Figure 3). Notably, the MAPT p.P301L muta-
tion is thought to enhance 4R aggregation,37 whereas the
IVS10 þ 16 mutation is thought to increase splicing to
generate more 4R tau isoforms.1
These results are similar to observations of relative
minimal AC-K274 reactivity in diffuse NTs in AD and
prominence of AC-274 in two cases of PSP and CBD and
one case of FTDP-1732; they also agree with our previous
observations of AC-K280 in sporadic AD and the non-
amyloid lesions seen in the 4R tauopathies, CBD and PSP.5
In light of the ﬁndings shown in this study, together with
our recent observations of tau autoacetylation,34 it is plau-
sible to infer that prominent K280-positive immunoreac-
tivity detected in neuronal and glial tau aggregates results
from abnormal tau enzymatic activity, leading to the accu-
mulation of autoacetylated tau proteins that no longer efﬁ-
ciently bind MTs. Whether aberrant tau autoacetylation is
triggered by tau phosphorylation within MTBD regions
remains to be determined. Indeed, we speculate that autoa-
cetylation likely drives the formation of predominantly
thioﬂavin-positive tau inclusions, explaining the striking
correlation between K280 immunoreactivity and tau
amyloid deposits in AD.5 However, given that we observed
K280-positive inclusions that were not thioﬂavin positive in
CBD, PSP,5 and FTDP-17, K280 acetylation also can occur
independent from the formation of tau amyloid. Further
studies in animal and cell models are needed to clarify the
role of AC-K280 and tau autoacetylation in tangle349
Irwin et alformation, including possible interplay with phospho-, neo-,
and other acetyl-epitopes of tau, based on these morpho-
logical observations. Nevertheless, AC-K280 represents
a signiﬁcant marker of tau deposition in these diverse 4R-
containing tauopathies resulting from multiple pathogenic
mechanisms, including intrinsic mutations in MAPT, muta-
tions in Ab-associated PSEN1, and age-associated neuro-
degenerative conditions, thereby demonstrating the
importance of this AC-K280 modiﬁcation of tau in disease
pathogenesis.Acknowledgments
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